VTVT
$1.63
Vtv Theraptcs Cl A
($.02)
(1.41%)
VTVT
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.10)
Revenue:  $0.00 Mil
Wednesday
Nov 4
4:30 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VTVT reports earnings?
Beat
Meet
Miss

Where is VTVT's stock price going from here?
Up
Flat
Down
Stock chart of VTVT
Analysts
Summary of analysts' recommendations for VTVT
Score
Grade
Pivots
Resistance
$1.76
$1.72
$1.69

$1.65

Support
$1.62
$1.58
$1.55
Tweet
Growth
Description
vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.